Skip to main content
Log in

Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Background

Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains controversial, and there is no uniform consensus in the literature. The present study was performed to evaluate treatment preference and outcomes for men with stage I testicular seminoma.

Materials and methods

From 1997 to 2013, 282 patients with histologically confirmed stage IA and IB testicular seminoma who underwent orchiectomy were included. The outcomes of three management options and survivals were retrospectively analyzed. The prognostic significance of risk factors for relapse on survival was evaluated by univariate and multivariate analysis; in addition, the factors predicting relapse were also evaluated by logistic regression analysis.

Results

Of the 282 patients with stage I seminoma, 130 (46.1) received adjuvant radiotherapy (RT), 80 (28.4 %) were treated with adjuvant carboplatin, while the remaining 72 patients (25.5 %) underwent surveillance. At the time of analysis, the median follow-up period of 38.5 months; relapses were observed in 16 patients (22.3 %) on surveillance, in one patient (1.2 %) treated with adjuvant carboplatin and in ten patients (%7.7) who received adjuvant RT. The 5-year disease-free survival (DFS) rate for patients who underwent surveillance was worse than those of patients treated with adjuvant carboplatin and RT (64.2 vs. 97.7 vs. 91.9 %, respectively; p < 0.001). However, the 5-year overall survival (OS) rate for patients on surveillance was similar compared with the adjuvant treatment groups (100 vs. 92.3 vs. 97.4 %, respectively; p = 0.44). Univariate analysis showed that only the treatment approach (surveillance vs. adjuvant carboplatin vs. adjuvant RT) for DFS (p < 0.001), invasion of the rete testis (p = 0.041) and the presence of relapse (p < 0.001) for OS were important prognostic indicators. Multivariate analysis indicated that the treatment strategy for DFS (p < 0.001, HR 0.34) was an independent prognostic factor. Furthermore, a logistic regression analysis showed that adjuvant treatment was found to be an independent factor for predicting relapse (p = 0.004, odds ratio: 0.39).

Conclusions

Our results indicate that adjuvant treatment with carboplatin or RT is associated with improved DFS compared with surveillance for men with stage I testicular seminoma after orchiectomy. Moreover, the treatment strategy is an important prognostic indicator for DFS and a predictive factor for relapse. Although adjuvant treatment, especially carboplatin, seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still feasible and the preferred management option after radical orchiectomy in men with stage I seminoma. More reliable predictive factors are needed to make treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  2. Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (2011) Pure seminoma: a review and update. Radiat Oncol 6:90

    Article  PubMed Central  PubMed  Google Scholar 

  3. Aparicio J, Diaz R (2010) Management options for stage I seminoma. Expert Rev Anticancer Ther 10:1077–1085

    Article  PubMed  Google Scholar 

  4. Chung P, Mayhew LA, Warde P, Winquist E, Lukka H, Genitourinary Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2010) Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 22:6–16

    Article  CAS  Google Scholar 

  5. Nallu A, Mannuel HD, Hussain A (2013) Testicular germ cell tumors: biology and clinical update. Curr Opin Oncol 25:266–272

    CAS  PubMed  Google Scholar 

  6. Osswald M, Harlan LC, Penson D, Stevens JL, Clegg LX (2009) Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol 27:604–610

    Article  PubMed Central  PubMed  Google Scholar 

  7. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365

    Article  PubMed  Google Scholar 

  8. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20:4448–4452

    Article  PubMed  Google Scholar 

  9. Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrústegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A (2005) Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717–8723

  10. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300

    Article  CAS  PubMed  Google Scholar 

  11. Aparicio J, Maroto P, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29:4677–4681

    Article  PubMed  Google Scholar 

  12. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, Goodman P, Jewett MA (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13:2255–2262

    CAS  PubMed  Google Scholar 

  13. AJCC (American Joint Committee on Cancer) (2010) In: Edge SB, Byrd DR, Compton CC et al (eds) Cancer staging manual, 7th edn. Springer, New York, p 117

  14. Chung P, Warde P (2006) Surveillance in stage I testicular seminoma. Urol Oncol 24:75–79

    Article  PubMed  Google Scholar 

  15. Tarin TV, Sonn G, Shinghal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181:627–632

    Article  PubMed  Google Scholar 

  16. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443–447

    Article  CAS  PubMed  Google Scholar 

  17. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29:957–962

    Article  CAS  PubMed  Google Scholar 

  18. Shin YS, Kim HJ (2013) Current management of testicular cancer. Korean J Urol 54:2–10

    Article  PubMed Central  PubMed  Google Scholar 

  19. Jones G, Arthurs B, Kaya H, Macdonald K, Qin R, Fairbanks RK, Lamoreaux WT, Jawed I, Tward JD, Martincic D, Shivnani AT, Lee CM (2013) Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis. Am J Clin Oncol 36:500–504

    Article  PubMed  Google Scholar 

  20. Leung E, Warde P, Jewett M, Panzarella T, O’Malley M, Sweet J, Moore M, Sturgeon J, Gospodarowicz M, Chung P (2013) Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int 112:1088–1095

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

This manuscript was not supported by any financial or other relationships. The authors declare that they have no conflict of interest.

Ethical standard

The study was approved by the Local Ethics Committee of hospitals and the informed written consents were obtained from each patients or their relatives.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ahmet Bilici.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bilici, A., Ozturk, T., Turkmen, E. et al. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology. World J Urol 33, 1613–1622 (2015). https://doi.org/10.1007/s00345-015-1492-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-015-1492-9

Keywords

Navigation